US2019209632A1PendingUtilityA1

Pharmaceutical Composition for Preventing and Treating Alpha Herpes Virus Infection, Containing, As Active Ingredient, Elaeocarpus Sylvestris Extract or Fraction Thereof

Assignee: GENENCELL CO LTDPriority: Sep 9, 2016Filed: Apr 28, 2017Published: Jul 11, 2019
Est. expirySep 9, 2036(~10.1 yrs left)· nominal 20-yr term from priority
A61K 2236/33A61K 31/365A61K 31/235A23L 33/105A23V 2002/00A61P 31/22A61K 36/185
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating alpha-herpesvirus infection comprising an Elaeocarpus sylvestris extract or a fraction thereof as an active ingredient, and can effectively prevent, treat or alleviate an alpha-herpesvirus and diseases caused thereby, such as herpes, encephalitis, genital herpes, chicken pox, or herpes zoster.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for preventing and treating alpha-herpesvirus infection comprising an  Elaeocarpus sylvestris  extract or a fraction thereof as an active ingredient. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the  Elaeocarpus sylvestris  extract is obtained by extraction with water, a lower alcohol having 1 to 4 carbon atoms, or a mixture thereof. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the  Elaeocarpus sylvestris  extract is a 50% ethanol extract. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the alpha-herpesvirus is one or more viruses selected from among varicella-zoster virus (VZV), herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2). 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the alpha-herpesvirus infection is any one or more selected from among herpes, genital herpes, chickenpox, and herpes zoster. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the  Elaeocarpus sylvestris  extract comprises any one or more selected from the group consisting of methyl gallate, geraniin and casuarictin. 
     
     
         7 . A pharmaceutical formulation for preventing and treating alpha-herpesvirus infection comprising an  Elaeocarpus sylvestris  extract or a fraction thereof as an active ingredient. 
     
     
         8 . A health food for preventing and alleviating alpha-herpesvirus infection comprising an  Elaeocarpus sylvestris  extract or a fraction thereof as an active ingredient. 
     
     
         9 . The health food of  claim 8 , wherein the  Elaeocarpus sylvestris  extract is obtained by extraction with water, a lower alcohol having 1 to 4 carbon atoms, or a mixture thereof. 
     
     
         10 . The health food of  claim 8 , wherein the alpha-herpesvirus is one or more viruses selected from among varicella-zoster virus (VZV), herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2). 
     
     
         11 . The health food of  claim 8 , wherein the alpha-herpesvirus infection is one or more selected from among herpes, encephalitis, genital herpes, chickenpox, and herpes zoster. 
     
     
         12 . The health food of  claim 8 , wherein the  Elaeocarpus sylvestris  extract comprises any one or more selected from the group consisting of methyl gallate, geraniin and casuarictin.

Join the waitlist — get patent alerts

Track US2019209632A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.